PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 11877768-3 2002 The aim of this study was to evaluate, in a subsequent Phase II trial, the therapeutic efficacy of this (131)I-labeled humanized anti-CEA antibody in colorectal cancer patients with small-volume disease or in an adjuvant setting. Iodine-131 104-110 CEA cell adhesion molecule 3 Homo sapiens 134-137 9615730-0 1998 Adjuvant 131I-anti-CEA-antibody radioimmunotherapy inhibits the development of experimental colonic carcinoma liver metastases. Iodine-131 9-13 CEA cell adhesion molecule 3 Homo sapiens 19-22 9716032-8 1998 The anti-CEA IgG1 monoclonal antibody A5B7 was radiolabelled with iodine-131 and administered intravenously to sheep. Iodine-131 66-76 CEA cell adhesion molecule 3 Homo sapiens 9-12 9615730-3 1998 Within half an hour, 20 MBq (n = 2), 75 MBq (n = 5), or 150 MBq (n = 10) of the 131I-labelled anti- carcinoembryonic antigen (CEA) monoclonal antibody (MAb) 38S1 was administered intravenously (i.v. Iodine-131 80-84 CEA cell adhesion molecule 3 Homo sapiens 100-124 9406734-3 1997 METHODS: Ninety-nine patients who received 131I-labeled anti-CEA MoAb for the treatment of CEA-producing cancers were assessed for platelet and white blood cell toxicity based on the common Radiation Therapy Oncology Group criteria. Iodine-131 43-47 CEA cell adhesion molecule 3 Homo sapiens 91-94 9406734-0 1997 Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies. Iodine-131 68-72 CEA cell adhesion molecule 3 Homo sapiens 81-110 9406734-2 1997 The authors investigated various factors potentially affecting hematologic toxicity after RAIT with 131I-labeled anti-carcinoembryonic antigen (CEA) MoAb to identify the statistically significant factors from those commonly perceived clinically to substantially contribute to this toxicity. Iodine-131 100-104 CEA cell adhesion molecule 3 Homo sapiens 113-142 9406734-2 1997 The authors investigated various factors potentially affecting hematologic toxicity after RAIT with 131I-labeled anti-carcinoembryonic antigen (CEA) MoAb to identify the statistically significant factors from those commonly perceived clinically to substantially contribute to this toxicity. Iodine-131 100-104 CEA cell adhesion molecule 3 Homo sapiens 144-147 9406734-3 1997 METHODS: Ninety-nine patients who received 131I-labeled anti-CEA MoAb for the treatment of CEA-producing cancers were assessed for platelet and white blood cell toxicity based on the common Radiation Therapy Oncology Group criteria. Iodine-131 43-47 CEA cell adhesion molecule 3 Homo sapiens 61-64 9466665-0 1998 Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab")2 in patients with non-resectable liver metastases from colorectal cancer. Iodine-131 42-52 CEA cell adhesion molecule 3 Homo sapiens 66-69 9466665-1 1998 Experimental studies in nude mice with human colon-carcinoma grafts demonstrated the therapeutic efficiency of F(ab")2 fragments to carcinoembryonic antigen (CEA) labeled with a high dose of 131Iodine. Iodine-131 191-200 CEA cell adhesion molecule 3 Homo sapiens 132-156 9466665-1 1998 Experimental studies in nude mice with human colon-carcinoma grafts demonstrated the therapeutic efficiency of F(ab")2 fragments to carcinoembryonic antigen (CEA) labeled with a high dose of 131Iodine. Iodine-131 191-200 CEA cell adhesion molecule 3 Homo sapiens 158-161 9074529-3 1997 The patients underwent radioimmunotherapy with the 131I-labeled IgG1 anti-CEA antibodies NP-4 (Ka = 10(8) M-1) or MN-14 (Ka = 10(9) M-1), its humanized form hMN-14, as well as the anticolon-specific antigen-p (CSAp) antibody, Mu-9. Iodine-131 51-55 CEA cell adhesion molecule 3 Homo sapiens 74-77 9189130-1 1997 UNLABELLED: The aim of this study was to determine, in a Phase I/II clinical trial, the pharmacokinetics, dosimetry and toxicity, as well as antitumor activity, of the 131I-labeled murine anti-carcinoembryonic antigen (CEA) monoclonal antibody, NP-4 (IgG1 subtype). Iodine-131 168-172 CEA cell adhesion molecule 3 Homo sapiens 219-222 9393755-3 1997 Nude mice, bearing s.c. xenografts of the human MTC cell line, TT, were treated either with the 131I-labeled anti-CEA MAb, F023C5 IgG, or were administered chemotherapeutic regimens that had shown promising results in patients with metastatic MTC (doxorubicin and cisplatinum monotherapy, combinations of both agents, and a 5-fluorouracil/dacarbazine/streptozotocin scheme). Iodine-131 96-100 CEA cell adhesion molecule 3 Homo sapiens 114-117 9025751-0 1997 Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody. Iodine-131 62-72 CEA cell adhesion molecule 3 Homo sapiens 86-89 8683309-0 1996 Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. Iodine-131 52-62 CEA cell adhesion molecule 3 Homo sapiens 76-79 8656248-13 1996 These data suggest that patients with highly elevated circulating CEA levels and/or increased tumor bulk may clear 131I-labeled COL-1 more rapidly from the circulation and experience less myelosuppression. Iodine-131 115-119 CEA cell adhesion molecule 3 Homo sapiens 66-69 8790202-0 1996 Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab")2. Iodine-131 62-72 CEA cell adhesion molecule 3 Homo sapiens 86-89 8683309-2 1996 METHODS: Eighteen patients with advanced MTC entered exploratory clinical studies with therapeutic doses of 131I-labeled NP-4 and MN-14 murine monoclonal antibodies (MAbs) reactive with carcinoembryonic antigen (CEA). Iodine-131 108-112 CEA cell adhesion molecule 3 Homo sapiens 186-210 8080740-1 1994 Studies in animal tumour models of colorectal cancer suggest that F(ab")2 antibody fragments to carcinoembryonic antigen (CEA) labelled with iodine-131 give superior therapy compared with intact anti-CEA antibody. Iodine-131 141-151 CEA cell adhesion molecule 3 Homo sapiens 96-120 8080740-1 1994 Studies in animal tumour models of colorectal cancer suggest that F(ab")2 antibody fragments to carcinoembryonic antigen (CEA) labelled with iodine-131 give superior therapy compared with intact anti-CEA antibody. Iodine-131 141-151 CEA cell adhesion molecule 3 Homo sapiens 122-125 7812699-0 1994 Detection of lymph node metastases in lung cancer: comparison of 131I-anti-CEA-anti-CA 19-9 immunoscintigraphy versus computed tomography. Iodine-131 65-69 CEA cell adhesion molecule 3 Homo sapiens 75-78 2010308-1 1991 Immunoscintigraphy after submucosal administration of a mixture of 131I-anti-CEA and 131I-anti-CA-19-9 around the tumor in patients with rectal carcinoma may improve pre-operative staging and may contribute to the selection of patients eligible for local treatment. Iodine-131 67-71 CEA cell adhesion molecule 3 Homo sapiens 77-80 1451056-9 1992 CONCLUSIONS: The results of these experiments show that hyperthermia increased the effectiveness of iodine-131-labeled anti-CEA monoclonal antibodies against human colon carcinoma xenografts in nude mice. Iodine-131 100-110 CEA cell adhesion molecule 3 Homo sapiens 124-127 1322378-1 1992 We evaluated the accretion of 131I-labeled NP-4 anticarcinoembryonic antigen (CEA) into 4 size-matched human colonic carcinomas grown s.c. in nude mice. Iodine-131 30-34 CEA cell adhesion molecule 3 Homo sapiens 78-81 1657845-1 1991 Previous experience using 131I anti-CEA antibody, which irradiates at a variable low dose rate in combination with a multimodality treatment program, has demonstrated acceptable toxicity and response in primary intrahepatic cholangiocarcinoma. Iodine-131 26-30 CEA cell adhesion molecule 3 Homo sapiens 36-39 1657845-14 1991 The mechanism of 131I-anti-CEA variable low dose irradiation and chemotherapy interaction is discussed as well as further potential modifications for treatment improvement. Iodine-131 17-21 CEA cell adhesion molecule 3 Homo sapiens 27-30 2004846-8 1991 The nadir platelet count was related to the half-life of 131I anti-CEA in blood. Iodine-131 57-61 CEA cell adhesion molecule 3 Homo sapiens 67-70 8204403-1 1994 A total of 7 (4 males and 3 females) patients were included in this retrospective study to determine the sensitivity of radioimmunoscintigraphy with I-131 labeled anti CEA/CA 19-9 monoclonal antibodies. Iodine-131 149-154 CEA cell adhesion molecule 3 Homo sapiens 168-171 8277212-2 1993 A number of different MAbs were employed (anti-CEA and anti-Tenascin) which were labelled with I-131. Iodine-131 95-100 CEA cell adhesion molecule 3 Homo sapiens 47-50 8384868-2 1993 IMACIS-1 is a radiopharmaceutical containing a mixture of Iodine-131 labeled monoclonal antibodies to CEA and CA19-9. Iodine-131 58-68 CEA cell adhesion molecule 3 Homo sapiens 102-105 8518021-0 1993 Potential contribution of 131I-labelled monoclonal anti-CEA antibodies in the treatment of liver metastases from colorectal carcinomas: pretherapeutic study with dose recovery in resected tissues. Iodine-131 26-30 CEA cell adhesion molecule 3 Homo sapiens 56-59 1464034-2 1992 At the experimental level, our group has shown that the intravenous injection of large doses of 131I labeled F(ab")2 fragments from monoclonal anti-carcinoembryonic antigen (CEA) antibodies can eradicate well established human colon carcinoma xenografts in nude mice. Iodine-131 96-100 CEA cell adhesion molecule 3 Homo sapiens 174-177 1995488-0 1991 The effect of radiosensitizers on radio-immunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft model. Iodine-131 61-65 CEA cell adhesion molecule 3 Homo sapiens 80-83 12412766-5 1989 131I-labelled goat anti-CEA or mouse monoclonal 17-1A first antibody and unlabelled horse angi-goat or rabbit anti-mouse second antibody, respectively. Iodine-131 0-4 CEA cell adhesion molecule 3 Homo sapiens 24-27 2231001-0 1990 Radioimmunoscintigraphy using iodine-131-anti-CEA monoclonal antibodies and thallium-201 scintigraphy in medullary thyroid carcinoma: a case report. Iodine-131 30-40 CEA cell adhesion molecule 3 Homo sapiens 46-49 3209304-3 1988 Continuous control of pressure, flow, temperature, pH and various metabolic parameters were performed after administration of 131I-labelled anti-CEA antibody. Iodine-131 126-130 CEA cell adhesion molecule 3 Homo sapiens 145-148 2789951-1 1989 The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Iodine-131 20-30 CEA cell adhesion molecule 3 Homo sapiens 59-83 2789951-1 1989 The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Iodine-131 20-30 CEA cell adhesion molecule 3 Homo sapiens 85-88 2789951-1 1989 The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Iodine-131 32-36 CEA cell adhesion molecule 3 Homo sapiens 59-83 2789951-1 1989 The distribution of iodine-131 (131I) labelled antibody to carcinoembryonic antigen (CEA) has been studied in 16 patients with colorectal cancer. Iodine-131 32-36 CEA cell adhesion molecule 3 Homo sapiens 85-88 2655889-1 1989 F(ab")2 fragments of anti-carcinoembryonic antigen (CEA) monoclonal antibody F023C5, determined to be more suitable than intact IgG and Fab fragments for immunoscintigraphy, were labeled with 131I or conjugated to DTPA for instant 111In-labeling, and administered i.v. Iodine-131 192-196 CEA cell adhesion molecule 3 Homo sapiens 21-50 2639132-6 1989 These preliminary results suggest that 131I anti-CEA scanning may be the most sensitive noninvasive method for the localization of MTC recurrences. Iodine-131 39-43 CEA cell adhesion molecule 3 Homo sapiens 49-52 3217256-1 1988 Solitary liver metastases (carcinoembryogenic antigen positive) in two patients suffering from colon carcinoma were multifocally injected with 131I-labelled monoclonal antibodies (131I-MAb) against the carcinoembryogenic antigen (CEA). Iodine-131 143-147 CEA cell adhesion molecule 3 Homo sapiens 230-233 3258293-1 1988 Quantitation from planar imaging and single photon emission computed tomography (SPECT) were compared in phantom studies and in patients receiving therapeutic doses of 131I-labelled anti-CEA. Iodine-131 168-172 CEA cell adhesion molecule 3 Homo sapiens 187-190 3258293-3 1988 The limitations of both methods were examined using the phantom studies and it was shown that practical SPECT quantitation could be achieved in patients given therapeutic doses of 131I-labelled anti-CEA, and furthermore, that SPECT appeared to give a more accurate estimate of the activity concentration. Iodine-131 180-184 CEA cell adhesion molecule 3 Homo sapiens 199-202 2715009-0 1989 Role of 131I-labelled anti-CEA/CA 19-9 monoclonal antibodies in the diagnosis and follow-up of gastrointestinal tumors. Iodine-131 8-12 CEA cell adhesion molecule 3 Homo sapiens 27-30 3235853-1 1988 131I-labelled anti-CEA monoclonal antibody was tested in an animal model to evaluate: influence of antibody type (whole versus F(ab")2 fragments), administration route (i.v. Iodine-131 0-4 CEA cell adhesion molecule 3 Homo sapiens 19-22 3335416-0 1988 Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Iodine-131 47-51 CEA cell adhesion molecule 3 Homo sapiens 77-80 3335416-12 1988 injection of 131I-labelled anti-CEA MAbs. Iodine-131 13-17 CEA cell adhesion molecule 3 Homo sapiens 32-35 3048746-1 1988 Early studies of immunoscintography with affinity-purified 131I-labeled polyclonal antibodies reactive against oncofetal antigens such as carcinoembryonic antigen (CEA) were moderately successful in detecting metastatic colorectal carcinoma. Iodine-131 59-63 CEA cell adhesion molecule 3 Homo sapiens 138-162 3048746-1 1988 Early studies of immunoscintography with affinity-purified 131I-labeled polyclonal antibodies reactive against oncofetal antigens such as carcinoembryonic antigen (CEA) were moderately successful in detecting metastatic colorectal carcinoma. Iodine-131 59-63 CEA cell adhesion molecule 3 Homo sapiens 164-167 3449789-1 1987 Two monoclonal antibodies to carcinoembryonic antigen (CEA) were radiolabelled with 131I and used for the treatment of hepatic metastases in a patient who had a primary colonic carcinoma. Iodine-131 84-88 CEA cell adhesion molecule 3 Homo sapiens 29-53 3449789-1 1987 Two monoclonal antibodies to carcinoembryonic antigen (CEA) were radiolabelled with 131I and used for the treatment of hepatic metastases in a patient who had a primary colonic carcinoma. Iodine-131 84-88 CEA cell adhesion molecule 3 Homo sapiens 55-58 3449789-7 1987 Regional administration of 131I-labelled anti-CEA antibody concurrently with biodegradable starch microspheres appears to be a promising new method for the treatment of hepatic metastases from colonic carcinoma. Iodine-131 27-31 CEA cell adhesion molecule 3 Homo sapiens 46-49 3677890-1 1987 In patients with local recurrence or liver metastases from colorectal cancer the preoperative results of conventional diagnostic methods (sonography, computed tomography, x-ray, endoscopy) and immunoscintigraphy performed with 131I labeled CEA/Ca 19-9 antibodies were compared to intraoperative findings. Iodine-131 227-231 CEA cell adhesion molecule 3 Homo sapiens 240-243 3501573-1 1987 Radioimmunoscintigraphy (RIS) with 111In-and 131I-labelled monoclonal antibodies (MAbs) against CEA and/or CA 19-9 was performed in 83 patients with various gastrointestinal carcinomas. Iodine-131 45-49 CEA cell adhesion molecule 3 Homo sapiens 96-99 3622555-0 1987 Tumor scintigraphy with 131I anti CEA monoclonal antibodies and F(ab")2 in colorectal cancer. Iodine-131 24-28 CEA cell adhesion molecule 3 Homo sapiens 34-37 3032877-3 1987 One month after external beam therapy, chemotherapy was given (Adriamycin, 15 mg + 5-FU, 500 mg) followed the next day by the first administration of 131I anti-CEA. Iodine-131 150-154 CEA cell adhesion molecule 3 Homo sapiens 160-163 3548950-1 1987 The simultaneous distribution of monoclonal 131I-labeled anti-carcinoembryonic antigen (CEA) immunoglobulin (IgG) (NP-2) or 131I-labeled irrelevant myeloma IgG (Ag8) and [3H]thymidine was studied in hamsters bearing transplants of the GW-39 human colon carcinoma by qualitative double-tracer whole-body autoradiography. Iodine-131 44-48 CEA cell adhesion molecule 3 Homo sapiens 88-91 3548950-5 1987 In confirmation of earlier reports, 131I-labeled anti-CEA monoclonal antibody gave higher tumor-to-non-tumor labeling patterns than did control 131I-labeled IgG, at both 3 and 7 days following treatment. Iodine-131 36-40 CEA cell adhesion molecule 3 Homo sapiens 54-57 3821910-1 1987 Tumor localization by a 131I-labeled monoclonal antibody to CEA has been evaluated in a series of 50 patients with clinically suspected primary or recurrent gastrointestinal cancer. Iodine-131 24-28 CEA cell adhesion molecule 3 Homo sapiens 60-63 3713682-7 1986 In four patients with liver metastasis from colorectal carcinoma, external photoscanning was also performed for radioimmunodetection of cancer with 131I-labeled antibody to CEA. Iodine-131 148-152 CEA cell adhesion molecule 3 Homo sapiens 173-176 3820841-0 1986 [Enhanced binding of 131I-labeled monoclonal anti-CEA antibody to a CEA producing lung carcinoma cell line (QG56) after phorbol ester (TPA) treatment]. Iodine-131 21-25 CEA cell adhesion molecule 3 Homo sapiens 50-53 3820841-0 1986 [Enhanced binding of 131I-labeled monoclonal anti-CEA antibody to a CEA producing lung carcinoma cell line (QG56) after phorbol ester (TPA) treatment]. Iodine-131 21-25 CEA cell adhesion molecule 3 Homo sapiens 68-71 3867855-1 1985 Experimental animal studies with 131I-labeled monoclonal antibodies against CA 19-9, CEA and CA 125]. Iodine-131 33-37 CEA cell adhesion molecule 3 Homo sapiens 85-88 6297651-2 1983 A number of external scintigraphic investigations have been carried out with 131I-labelled antibodies to carcinoembryonic antigen (CEA). Iodine-131 77-81 CEA cell adhesion molecule 3 Homo sapiens 105-129 6085756-6 1984 The five cholangiocarcinoma patients were treated with 131I-labeled anti-carcinoembryonic antigen (CEA). Iodine-131 55-59 CEA cell adhesion molecule 3 Homo sapiens 99-102 6085756-9 1984 The radiation dose to cholangiocarcinomas from 131I-labeled anti-CEA and administered activities of 20 mCi on day 0 and 10 mCi on day 5 was approximately 620 rads. Iodine-131 47-51 CEA cell adhesion molecule 3 Homo sapiens 65-68 6333200-4 1984 We used injections of 131-I labelled monoclonal antibodies to CEA and Tg to detect thyroid tumours. Iodine-131 22-27 CEA cell adhesion molecule 3 Homo sapiens 62-65 6409238-4 1983 Five of the patients also received 131I-anti-CEA. Iodine-131 35-39 CEA cell adhesion molecule 3 Homo sapiens 45-48 4075656-0 1985 Iodine-131 labeled anti-CEA antibodies uptake by Hurthle cell carcinoma. Iodine-131 0-10 CEA cell adhesion molecule 3 Homo sapiens 24-27 4075656-1 1985 Localization of Hurthle cell cancer deposits in the lung with I-131 labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody is described. Iodine-131 62-67 CEA cell adhesion molecule 3 Homo sapiens 76-105 4075656-1 1985 Localization of Hurthle cell cancer deposits in the lung with I-131 labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody is described. Iodine-131 62-67 CEA cell adhesion molecule 3 Homo sapiens 107-110 6297651-2 1983 A number of external scintigraphic investigations have been carried out with 131I-labelled antibodies to carcinoembryonic antigen (CEA). Iodine-131 77-81 CEA cell adhesion molecule 3 Homo sapiens 131-134 286108-4 1979 HCBP was shown to bind radioiodine-labeled CEA both by a radioimmune precipitation assay and by a radioimmunoelectrophoresis assay. Iodine-131 23-34 CEA cell adhesion molecule 3 Homo sapiens 43-46 7471071-1 1980 131I-labeled goat immunoglobulin G (IgG) prepared against carcinoembryonic antigen (CEA) was administered at an average dose of 1.0 mCi (180 to 250 microgram IgG protein) to patients with ovarian tumors in order to evaluate this method of tumor detection and localization, termed the radioimmunodetection of cancer. Iodine-131 0-4 CEA cell adhesion molecule 3 Homo sapiens 59-83 7471071-1 1980 131I-labeled goat immunoglobulin G (IgG) prepared against carcinoembryonic antigen (CEA) was administered at an average dose of 1.0 mCi (180 to 250 microgram IgG protein) to patients with ovarian tumors in order to evaluate this method of tumor detection and localization, termed the radioimmunodetection of cancer. Iodine-131 0-4 CEA cell adhesion molecule 3 Homo sapiens 85-88 7427084-1 1980 Sheep IgG antibody to carcinoembryonic antigen (CEA) was radiolabelled with 131I and used to identify human gastrointestinal tumours by external subtraction imaging. Iodine-131 76-80 CEA cell adhesion molecule 3 Homo sapiens 22-46 7427084-1 1980 Sheep IgG antibody to carcinoembryonic antigen (CEA) was radiolabelled with 131I and used to identify human gastrointestinal tumours by external subtraction imaging. Iodine-131 76-80 CEA cell adhesion molecule 3 Homo sapiens 48-51 7357516-4 1980 Three additional cases were evaluated; one had a villous adenoma in the rectum and received the 131-I-labelled anti-CEA IgG, while two colonic carcinoma patients received normal goat IgG labelled with 131-I. Iodine-131 96-101 CEA cell adhesion molecule 3 Homo sapiens 116-119 7008935-1 1980 The circulating radioactivity and antibody immunoreactivity in patients with diverse cancers who had received 131I-labeled goat antibodies to carcinoembryonic antigen (CEA) were studied by Sephadex G-200 column chromatography and with solid-phase (SP) immunoadsorbents containing anti-goat immunoglobulin G(IgG), anti-human IgG, anti-CEA, or CEA. Iodine-131 110-114 CEA cell adhesion molecule 3 Homo sapiens 142-166 7008935-1 1980 The circulating radioactivity and antibody immunoreactivity in patients with diverse cancers who had received 131I-labeled goat antibodies to carcinoembryonic antigen (CEA) were studied by Sephadex G-200 column chromatography and with solid-phase (SP) immunoadsorbents containing anti-goat immunoglobulin G(IgG), anti-human IgG, anti-CEA, or CEA. Iodine-131 110-114 CEA cell adhesion molecule 3 Homo sapiens 168-171 20078028-0 2010 Radioimmunotherapy of human colon cancer xenografts with 131I-labeled anti-CEA monoclonal antibody. Iodine-131 57-61 CEA cell adhesion molecule 3 Homo sapiens 75-78 20078028-2 2010 The aim of this study was to investigate the therapeutic efficacy of (131)I-labeled anticarcinoembryonic antigen (CEA) monoclonal antibody CL58 in a human colon cancer mouse model. Iodine-131 69-75 CEA cell adhesion molecule 3 Homo sapiens 114-117